Device Trial Radar · NCT05782556
Freiburg TIPS Registry
Last checked: Nov 20, 2026Latest source record: May 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
2,000
Planned (sponsor's estimate)
Start
Jan 1, 2023
Primary completion
Dec 31, 2033
Study completion Jun 30, 2034
Sponsor
- Lead sponsor
- University Hospital FreiburgAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 23, 2023
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Patients with clinically significant portal hypertension allocated to implantation of a transjugular intrahepatic portosystemic shunt (TIPS) at the Department of Medicine II of the University Medical Center Freiburg, Germany will be offered to participate in this prospective observational trial. Clinical and laboratory as well as outcome parameters will be assessed before and within the first 12 months after TIPS implantation following a regular follow-up schedule with clinical visits at the University Medical Center Freiburg. During follow-up visits, serum/plasma samples and peripheral blood mononuclear cells (PBMC) are collected and stored in a associated biobank.
Conditions
- Liver Cirrhosis
- Portal Hypertension
- Non-Cirrhotic Portal Hypertension
- Budd Chiari Syndrome
- Portal Vein Thrombosis
- Portal Systemic Shunt
Interventions
Implantation of a transjugular intrahepatic portosystemic shunt (TIPS)Device
For TIPS implantation, a transjugular approach is used in all patients and a puncture needle was advanced into a hepatic vein. Puncture of the portal vein is performed using ultrasound guidance followed by portography after successful puncture of the portal vein. Further, the parenchymal tract isdilated and the stent graft is placed. Before and after TIPS implantation, portal venous and central venous pressures are measured to calculate the porto-systemic pressure gradient
Primary outcomes
What the sponsor says the trial is designed to measure.
- Transplantation-free survivalTime frame: 01/01/2023-31/12/2033
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University Medical Center Freiburg, Department of Medicine II
Freiburg im Breisgau, Germany · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.